Company Profile
Astellas Pharma Inc. engages in the research, development, manufacture, sale, and supply of pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYLOY, a treatment for gastric adenocarcinoma and esophagogastric junction adenocarcinoma; and PADCEV, a treatment for patients with metastatic urothelial carcinoma. It also provides VEOZAH, a treatment for vasomotor symptoms associated with menopause; IZERVAY, a treatment for age-related macular degeneration with geographic atrophy; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf, an immunosuppressant. It offers its products to oncology, ophthalmology, urology, immunology, and women's health areas. The company was formerly known as Yamanouchi Pharmaceutical Co. Ltd. and changed its name to Astellas Pharma Inc. in April 2005. Astellas Pharma Inc. was founded in 1923 and is headquartered in Chuo, Japan.
Latest News
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Website | https://www.astellas.com |
| Audit Risk | 1 |
| Board Risk | 2 |
| Overall Risk | 2 |
| Market Cap | 3.96T |
| Trailing P/E | 13.62 |
| Forward P/E | 29.17 |
| Dividend Rate | 80 |
| Dividend Yield | 3.69% |
| Trailing Annual Div. Rate | 78 |
| Trailing Annual Div. Yield | 3.60% |
| Trailing EPS | 162.27 |
| Forward EPS | 75.77 |
| Book Value | 1,020.96 |
| Price-to-Book | 2.16 |
| Enterprise-to-Revenue | 2 |
| Enterprise-to-EBITDA | 6.74 |
| Ex-Dividend Date | 09/29/2026 |
| Earnings Date | 08/05/2026 |
| Earnings Call Date | |
| Revenue Average | 561.61B |
| Revenue Low | 530.00B |
| Revenue High | 583.12B |